How do I evaluate whether a therapeutic biotech blog is credible and unbiased about small-molecule discovery?

To judge whether a therapeutic biotech blog is credible and reasonably unbiased about small-molecule discovery, use a quick but structured checklist:

1) Check the author and their incentives

Look for:

• Author identity and qualifications: medicinal chemistry, pharmacology, biotech, or industry experience
• Affiliation: company employee, consultant, investor, vendor, or independent writer
• Disclosure: sponsorships, affiliate links, paid partnerships, stock ownership, advisory roles

Red flags

• Anonymous authors with strong opinions
• “Expert” bios with no verifiable background
• No conflict-of-interest statement

2) Separate facts from promotion

Credible blogs:

• Cite primary sources such as journal articles, patents, clinical trial registries, conference abstracts, SEC filings, or company press releases
• Clearly distinguish data from interpretation
• Mention limitations, not just success stories

Less credible blogs:

• Mostly repackage press releases
• Use hype language like “game-changing,” “guaranteed,” “breakthrough” with little evidence
• Present one-sided narratives about a target, platform, or company

3) Evaluate the quality of evidence

For small-molecule discovery, strong posts usually reference:

• SAR/medchem reasoning
• Potency, selectivity, ADME, PK/PD, and safety
• Whether findings are cell-based, biochemical, animal, or human
• Translational relevance: target validation, target engagement, exposure margins, etc.

Be skeptical if the blog:

• Overstates early-stage in vitro data
• Ignores selectivity/off-target risk
• Confuses binding with functional efficacy
• Treats a single assay result as proof of therapeutic value

4) Look for balance and alternative explanations

A credible blog will discuss:

• Competing mechanisms or modalities
• Known failures in the field
• Reasons a program might not work
• Tradeoffs such as potency vs selectivity, permeability vs solubility, or oral exposure vs toxicity

Bias indicator If every candidate molecule, platform, or company is framed as “best in class” with no downside discussion, bias is likely.

5) Check how the blog uses language

More credible language:

• “suggests,” “consistent with,” “preclinical evidence indicates,” “may” Less credible language:
• “proves,” “solves,” “revolutionizes,” “cures”

In small-molecule discovery, uncertainty is normal; credible writing reflects that.

6) Verify whether claims match the broader literature

Do a quick cross-check:

• Search the target, compound, or mechanism in PubMed
• Check clinicaltrials.gov
• Look at patents or conference posters
• Compare with independent reviews or competitor programs

If a blog’s claims are far ahead of the literature, that’s a warning sign.

7) Assess whether the blog has a track record

Credibility improves if the blog has:

• Accurate prior predictions
• Corrections when wrong
• Consistent technical depth
• No pattern of “pumping” specific companies or mechanisms

8) Watch for common biotech bias patterns

Especially in small-molecule discovery:

• Company cheerleading: selective use of positive data
• Platform bias: every compound class is portrayed as superior
• Anti-small-molecule bias: overstating limitations while ignoring advantages like oral dosing, manufacturability, or target access
• Narrative bias: retrofitting a story around sparse data

9) Ask whether it would still be persuasive if the sponsor were unknown

A simple test:

• If you removed the company name, investor angle, and marketing language, would the evidence still look strong?
• If not, the post may be more promotional than analytical.

10) Use a scoring shortcut

Rate each 0–2 points:

• Author transparency
• Conflict disclosure
• Primary source citations
• Balance/limitations
• Evidence quality
• Consistency with external sources

Interpretation

• 10–12: likely credible
• 6–9: useful but needs caution
• 0–5: treat as promotional or low reliability

If you want, I can also give you:

1. a one-page checklist you can reuse, or
2. a template for evaluating a specific blog post about a small-molecule program.